Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Connected Health Exercise Consultation Case Study: A Weight Management Strategy Post Gastric Bypass Surgery
Paul, F. T., Fernandes, Regis, Cataldo, Donna, Scales, Robert , Paul, Frank, Katayama, Minako , Buras, Matthew

Mayo Clinic

Medicine & Science in Sports & Exercise | June 25, 2019 | Volume: 51 | Issue: 6S | Pages: 838-838

10.1249/01.mss.0000563002.19954.cb Get It

Breaking3: Performance Characteristics Of A Sub-three-hour Septuagenarian Marathoner
Farquhar, William B. , Robinson, Austin T. , Watso, Joseph C. , Babcock, Matthew C. , Joyner, Michael J.

Mayo Clinic

Medicine & Science in Sports & Exercise | June 25, 2019 | Volume: 51 | Issue: 6S | Pages: 311-311

10.1249/01.mss.0000561441.27829.35 Get It

Inhaled corticosteroids prescriptions increased in the ED for recurrent asthma exacerbations by automated electronic reminders in the ED
Farmer, Adam D. , Mirea, Lucia , Rank, Matthew A. , Bulloch, Blake, Vaidya, Vinay, Drewek, Rupali , Rank, Matthew, Mirea, Lucia , Carter, Jodi M.

Mayo Clinic

Journal of Asthma | June 21, 2019 | Volume: 57 | Issue: 10 | Pages: 1140-1144

10.1080/02770903.2019.1635152 | PMID 31226000 Get It

First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
Somaiah, Neeta , Block, Matthew S. , Kim, Joseph W. , Shapiro, Geoffrey I. , Khanh, T. , Hwu, Patrick , Jones, Robin L. , Meulen, Jan H. ter, Bohac, Chet, Hsu, Frank J., Gnjatic, Sacha , Gnjatic, Sacha , Jones, Robin L , Shapiro, Geoffrey I , Hwu, Patrick , Eder, Joseph P. , Lu, Hailing , Chen, Michael , Pollack, Seth M.

Mayo Clinic

Clinical Cancer Research | June 21, 2019 | Volume: 25 | Issue: 19 | Pages: 5808-5817

10.1158/1078-0432.ccr-19-1025 | PMID 31227504 Get It

Abstract Purpose: LV305 is a modified, third-generation, nonreplicating, integration-deficient lentivirus-based vector designed to selectively transduce dendritic cells in vivo. LV305 induces expression of the New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1) cancer testis antigen in dendritic cells, promoting immune responses against NY-ESO-1–expressing tumors. This phase I study evaluated the safety, immunogenicity, and preliminary efficacy of LV305 in patients with sarcoma or other solid tumors. Patients and Methods: Adults with previously treated, advanced, NY-ESO-1–positive solid tumors and limited tumor burden were eligible. LV305 was administered every 3 weeks by intradermal injection in four dose cohorts (Cohort 1: 108 vector genomes (vg) x 3 doses; Cohorts 1A, 2, and 3: 108 vg, 109 vg, 1010 vg x 4 doses). Results: Thirty-nine patients were enrolled: 3 patients each in Cohorts 1, 1A, and 2, and 30 patients in Cohort 3. No dose-limiting toxicities were observed. Tumor types included sarcoma (n = 24), ovarian (n = 8), melanoma (n = 6), and lung cancer (n = 1). All treatment-related adverse events were grade 1 or 2. Common treatment-related adverse events were fatigue (49%), injection site reactions (46%), and myalgia (21%). The disease control rate was 56.4% in all patients and 62.5% in sarcoma patients. One patient with synovial sarcoma achieved a partial response lasting >36 months. Anti–NY-ESO-1-specific CD4+ and/or CD8+ T cells were induced in 57% of evaluable sarcoma patients. Induction of an anti–NY-ESO-1 immune response was associated with improved 1-year survival in an exploratory analysis. Conclusions: This first-in-class, first-in-human study of LV305 demonstrated a favorable safety profile, induction of antigen-specific responses, and potential clinical activity in patients with advanced cancer.
A Viable Alternative When Propensity Scores Fail: Evaluation of Inverse Propensity Weighting and Sequential G-Estimation in a Two-Wave Mediation Model
MacKinnon, David P. , Mazza, Gina L. , MacKinnon, David P , Mazza, Gina L , Valente, Matthew J.

Mayo Clinic

Multivariate Behavioral Research | June 21, 2019 | Volume: 55 | Issue: 2 | Pages: 165-187

10.1080/00273171.2019.1614429 | PMID 31220937 Get It

Implementation of a patient blood management program in hematopoietic stem cell transplantation (Editorial, p. 2763)
Warner, Matthew A. , Jambhekar, Nilesh S., Saadeh, Salwa , Jacob, Eapen K., Kreuter, Justin D. , Mundell, William C., Marquez, Alberto , Higgins, Andrew , Madde, Nageswar R., Kor, Daryl J. , Higgins, Andrew A, Warner, Matthew A , Higgins, Andrew A., Hogan, William J.

Mayo Clinic

Transfusion | June 21, 2019 | Volume: 59 | Issue: 9 | Pages: 2840-2848

10.1111/trf.15414 | PMID 31222775 Get It

BACKGROUNDRecipients of hematopoietic stem cell transplantation (HSCT) are among the highest consumers of allogeneic red blood cell (RBC) and platelet (PLT) components. The impact of patient blood management (PBM) efforts on HSCT recipients is poorly understood.STUDY DESIGN AND METHODSThis observational study assessed changes in blood product use and patient‐centered outcomes before and after implementing a multidisciplinary PBM program for patients undergoing HSCT at a large academic medical center. The pre‐PBM cohort was treated from January 1 through September 31, 2013; the post‐PBM cohort was treated from January 1 through September 31, 2015.RESULTSWe identified 708 patients; 284 of 352 (80.7%) in the pre‐PBM group and 225 of 356 (63.2%) in the post‐PBM group received allogeneic RBCs (p < 0.001). Median (interquartile range [IQR]) RBC volumes were higher before PBM than after PBM (3 [2‐4] units vs. 2 [1‐4] units; p = 0.004). A total of 259 of 284 pre‐PBM patients (91.2%) and 57 of 225 (25.3%) post‐PBM patients received RBC transfusions when hemoglobin levels were more than 7 g/dL (p < 0.001). The median (IQR) PLT transfusion quantities was 3 (2‐5) units for pre‐PBM patients and 2 (1‐4) units for post‐PBM patients (p < 0.001). For patients with PLT counts of more than 10 × 109/L, a total of 1219 PLT units (73.4%) were transfused before PBM and 691 units (48.8%) were transfused after PBM (p < 0.001). Estimated transfusion expenditures were reduced by $617,152 (18.3%). We noted no differences in clinical outcomes or transfusion‐related adverse events.CONCLUSIONPatient blood management implementation for HSCT recipients was associated with marked reductions in allogeneic RBC and PLT transfusions and decreased transfusion‐related costs with no detrimental impact on clinical outcomes.
A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation
Carey, Elizabeth J. , Lai, Jennifer C. , Sonnenday, Christopher J. , Tapper, Elliot B. , Duarte‐Rojo, Andrés , Dunn, Michael A. , Tsien, Cynthia , Kallwitz, Eric R. , Ng, Vicky L. , Bashir, Mustafa R. , Montano-Loza, Aldo J , Lai, Jennifer , Duarte-Rojo, Andres , Tandon, Puneeta , Dasarathy, Srinivasan , Kappus, Matthew R. , Montaño‐Loza, Aldo J.

Mayo Clinic

Hepatology | June 20, 2019 | Volume: 70 | Issue: 5 | Pages: 1816-1829

10.1002/hep.30828 | PMID 31220351 Get It

Loss of muscle mass and function, or sarcopenia, is a common feature of cirrhosis and contributes significantly to morbidity and mortality in this population. Sarcopenia is a main indicator of adverse outcomes in this population, including poor quality of life, hepatic decompensation, mortality in patients with cirrhosis evaluated for liver transplantation (LT), longer hospital and intensive care unit stay, higher incidence of infection following LT, and higher overall health care cost. Although it is clear that muscle mass is an important predictor of LT outcomes, many questions remain, including the best modality for assessing muscle mass, the optimal cut‐off values for sarcopenia, the ideal timing and frequency of muscle mass assessment, and how to best incorporate the concept of sarcopenia into clinical decision making. For these reasons, we assembled a group of experts to form the North American Working Group on Sarcopenia in Liver Transplantation to use evidence from the medical literature to address these outstanding questions regarding sarcopenia in LT. We believe sarcopenia assessment should be considered in all patients with cirrhosis evaluated for liver transplantation. Skeletal muscle index (SMI) assessed by computed tomography constitutes the best‐studied technique for assessing sarcopenia in patients with cirrhosis. Cut‐off values for sarcopenia, defined as SMI < 50 cm 2 /m 2 in male and < 39 cm 2 /m 2 in female patients, constitute the validated definition for sarcopenia in patients with cirrhosis. Conclusion: The management of sarcopenia requires a multipronged approach including nutrition, exercise, and additional pharmacological therapy as deemed necessary. Future studies should evaluate whether recovery of sarcopenia with nutritional management in combination with an exercise program is sustainable as well as how improvement in muscle mass might be associated with improvement in clinical outcomes.
Evaluation of Medical School Grading Variability in the United States: Are All Honors the Same?
Westerman, Mary E. , Boe, Chelsea C., Bole, Raevti , Turner, Norman S. , Rose, Steven H., Gettman, Matthew T., Thompson, R. Houston, Westerman, Mary E

Mayo Clinic

Academic Medicine | June 20, 2019 | Volume: 94 | Issue: 12 | Pages: 1939-1945

10.1097/acm.0000000000002843 | PMID 31219812 Get It

Purpose The medical student performance evaluation (MSPE) summarizes a residency applicant’s academic performance. Despite attempts to improve standardized clerkship grading, concerns regarding grade inflation and variability at United States medical schools persist. This study’s aim was to describe current patterns of clerkship grading and applicant performance data provided in the MSPE. Method The authors evaluated Electronic Residency Application Service data submitted to a single institution for the 2016–2017 Match cycle. Clerkship grading characteristics regarding grading tiers, school rank, location, and size were obtained. Data regarding methods for summative comparisons such as key word utilization were also extracted. Descriptive statistics were generated, and generalized linear modeling was performed. Results Data were available for 137/140 (98%) MD-granting U.S. medical schools. Pass/fail grading was most commonly used during the preclinical years (47.4%). A 4-tier system was most common for clerkship grading (31%); however, 19 different grading schemes were identified. A median of 34% of students received the highest clerkship grade (range, 5%–97%). Students attending a top 20 medical school were more likely to receive the highest grade compared with those attending lower-rated schools (40% vs 32%, P < .001). Seventy-three percent of schools ranked students, most commonly using descriptive adjectives. Thirty-two different adjectives were used. Conclusions There is significant institutional variation in clinical grading practices and MSPE data. For core clerkships where most students received the highest grade, the ability to distinguish between applicants diminishes. A standardized approach to reporting clinical performance may allow for better comparison of residency applicants.
Tamoxifen Metabolism and Breast Cancer Recurrence: A Question Unanswered by CYPTAM
Nakamura, Yusuke , Kiyotani, Kazuma , Jordan, V. Craig , Ingle, James N. , Goetz, Matthew P. , Suman, Vera J.

Mayo Clinic

Journal of Clinical Oncology | June 18, 2019 | Volume: 37 | Issue: 22 | Pages: 1982-1983

10.1200/jco.19.00504 | PMID 31211604 Get It